Skip to main content
Top
Published in: International Urology and Nephrology 2/2024

26-09-2023 | Tadalafile | Urology - Original Paper

Efficacy of low-intensity shockwave therapy with different tadalafil regimens in patients with PDE5 inhibitor-resistant erectile dysfunction: a retrospective cohort study

Authors: Muhammed Arif İbis, Fatih Ozkaya, Zafer Tokatli, Cagri Akpinar, Onder Yaman

Published in: International Urology and Nephrology | Issue 2/2024

Login to get access

Abstract

Purpose

Currently, there is a lack of research comparing tadalafil treatment protocols recommended during low-intensity shock wave therapy (LI-SWT) for patients with erectile dysfunction (ED) who are unresponsive to phosphodiesterase type 5 inhibitors (PDE5i). The objective of this study is to compare the efficacy of only LI-SWT versus LI-SWT plus 5 mg tadalafil daily versus LI-SWT plus 20 mg tadalafil alternate-day in PDE5i -resistant ED.

Materıals and methods

In this study, a cohort of 105 patients with PDE5i-resistant ED was recruited and divided into three groups labeled as A (only LI-SWT), B (LI-SWT plus 5 mg tadalafil daily), and C (LI-SWT plus 20 mg tadalafil alternate-day), comprising 27, 42, and 36 patients, respectively. The patients' International Index of Erectile Function-5 (IIEF-5) scores and the Erection Hardness Score (EHS) were evaluated at the baseline, three months and six months following the treatment.

Results

After three months post-treatment, the IIEF-5 scores in group A, B, and C increased by 4.1 ± 0.6, 7.3 ± 0.6, and 8.2 ± 0.6, respectively. These improvements were maintained at six months with IIEF-5 scores increasing by 3.7 ± 0.6, 7.3 ± 0.6, and 8.5 ± 0.7 in groups A, B, and C, respectively. At 3 and 6 months post-treatment, groups B and C showed significant improvement in IIEF-5 scores and EHS values compared to group A (p < 0.001). The rate of patients with EHS ≥ 3 and IIEF-5 ≥ 17 was significantly higher in groups B and C compared to group A, while there was no significantly different between groups B and C.

Conclusıon

In patients with PDE5i-resistant ED, PDE5i combined with LI-SWT is superior to LI-SWT monotherapy. The statistical analysis failed to demonstrate any difference between two distinct tadalafil regimens when administered with LI-SWT treatment.
Literature
1.
go back to reference Gong B, Ma M, Xie W et al (2017) Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol 49:1731–1740CrossRefPubMedPubMedCentral Gong B, Ma M, Xie W et al (2017) Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol 49:1731–1740CrossRefPubMedPubMedCentral
3.
go back to reference McCabe MP, Matic H (2008) Erectile dysfunction and relationships: views of men with erectile dysfunction and their partners. Sex Relatsh Ther 23(1):51–60CrossRef McCabe MP, Matic H (2008) Erectile dysfunction and relationships: views of men with erectile dysfunction and their partners. Sex Relatsh Ther 23(1):51–60CrossRef
4.
go back to reference Althof SE, O’Leary MP, Cappelleri JC et al (2006) Impact of erectile dysfunction on confidence, self-esteem and relationship satisfaction after 9 months of sildenafil citrate treatment. J Urol 176(5):2132–2137CrossRefPubMed Althof SE, O’Leary MP, Cappelleri JC et al (2006) Impact of erectile dysfunction on confidence, self-esteem and relationship satisfaction after 9 months of sildenafil citrate treatment. J Urol 176(5):2132–2137CrossRefPubMed
5.
go back to reference Lee D, Nazroo J, Pendleton N (2015) Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men. Int J Impot Res 27(4):146–151CrossRefPubMed Lee D, Nazroo J, Pendleton N (2015) Erectile dysfunction and phosphodiesterase type 5 inhibitor use: associations with sexual activities, function and satisfaction in a population sample of older men. Int J Impot Res 27(4):146–151CrossRefPubMed
6.
go back to reference Vita R, Benvenga S, Giammusso B et al (2019) Determinants of early response to low-intensity extracorporeal shockwaves for the treatment of vasculogenic erectile dysfunction: an open-label, prospective study. J Clin Med 8(7):1017CrossRefPubMedPubMedCentral Vita R, Benvenga S, Giammusso B et al (2019) Determinants of early response to low-intensity extracorporeal shockwaves for the treatment of vasculogenic erectile dysfunction: an open-label, prospective study. J Clin Med 8(7):1017CrossRefPubMedPubMedCentral
7.
go back to reference Vinay J, Moreno D, Rajmil O et al (2021) Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double-blind sham-controlled clinical trial. World J Urol 39:2217–2222CrossRefPubMed Vinay J, Moreno D, Rajmil O et al (2021) Penile low intensity shock wave treatment for PDE5I refractory erectile dysfunction: a randomized double-blind sham-controlled clinical trial. World J Urol 39:2217–2222CrossRefPubMed
8.
go back to reference Mykoniatis I, Pyrgidis N, Sokolakis I et al (2021) Assessment of combination therapies vs monotherapy for erectile dysfunction: a systematic review and meta-analysis. JAMA Netw Open 4(2):e2036337CrossRefPubMedPubMedCentral Mykoniatis I, Pyrgidis N, Sokolakis I et al (2021) Assessment of combination therapies vs monotherapy for erectile dysfunction: a systematic review and meta-analysis. JAMA Netw Open 4(2):e2036337CrossRefPubMedPubMedCentral
9.
go back to reference Jeon SH, Shrestha KR, Kim RY et al (2016) Combination therapy using human adipose-derived stem cells on the cavernous nerve and low-energy shockwaves on the corpus cavernosum in a rat model of post-prostatectomy erectile dysfunction. Urology 88(226):e1–e9 Jeon SH, Shrestha KR, Kim RY et al (2016) Combination therapy using human adipose-derived stem cells on the cavernous nerve and low-energy shockwaves on the corpus cavernosum in a rat model of post-prostatectomy erectile dysfunction. Urology 88(226):e1–e9
10.
go back to reference Brock GB, McMahon CG, Chen K et al (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168(4):1332–1336CrossRefPubMed Brock GB, McMahon CG, Chen K et al (2002) Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol 168(4):1332–1336CrossRefPubMed
11.
go back to reference Brock G, Ni X, Oelke M et al (2016) Efficacy of continuous dosing of tadalafil once daily vs tadalafil on demand in clinical subgroups of men with erectile dysfunction: a descriptive comparison using the integrated tadalafil databases. J Sex Med 13(5):860–875CrossRefPubMedPubMedCentral Brock G, Ni X, Oelke M et al (2016) Efficacy of continuous dosing of tadalafil once daily vs tadalafil on demand in clinical subgroups of men with erectile dysfunction: a descriptive comparison using the integrated tadalafil databases. J Sex Med 13(5):860–875CrossRefPubMedPubMedCentral
12.
go back to reference Mirone V, Costa P, Damber J-E et al (2005) An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 47(6):846–854CrossRefPubMed Mirone V, Costa P, Damber J-E et al (2005) An evaluation of an alternative dosing regimen with tadalafil, 3 times/week, for men with erectile dysfunction: SURE study in 14 European countries. Eur Urol 47(6):846–854CrossRefPubMed
13.
go back to reference Nguyen Q, Van Do H (2022) Assessment of the results of treatment erectile dysfunction in diabetic patients by tadalafil 20mg once every there days. J Sex Med 19(5):S188CrossRef Nguyen Q, Van Do H (2022) Assessment of the results of treatment erectile dysfunction in diabetic patients by tadalafil 20mg once every there days. J Sex Med 19(5):S188CrossRef
14.
go back to reference Grandez-Urbina JA, Rodríguez RP, Torres-Román JS et al (2020) Low-intensity extracorporeal shock wave treatment improves erectile function in non-responder PDEi5 patients: a systematic review. Rev Int de Androl 19(4):272–280 Grandez-Urbina JA, Rodríguez RP, Torres-Román JS et al (2020) Low-intensity extracorporeal shock wave treatment improves erectile function in non-responder PDEi5 patients: a systematic review. Rev Int de Androl 19(4):272–280
15.
go back to reference Zhu GQ, Jeon SH, Bae WJ et al (2018) Efficient promotion of autophagy and angiogenesis using mesenchymal stem cell therapy enhanced by the low-energy shock waves in the treatment of erectile dysfunction. Stem Cells Int 2018:14CrossRef Zhu GQ, Jeon SH, Bae WJ et al (2018) Efficient promotion of autophagy and angiogenesis using mesenchymal stem cell therapy enhanced by the low-energy shock waves in the treatment of erectile dysfunction. Stem Cells Int 2018:14CrossRef
16.
go back to reference Ruffo A, Stanojevic N, Romeo G et al (2020) PS-5-3 management of erectile dysfunction using a combination treatment of low-intensity shock waves (LISW) and platelet rich plasma (PRP) intracavernosal injections. J Sex Med 17(6):S133–S134CrossRef Ruffo A, Stanojevic N, Romeo G et al (2020) PS-5-3 management of erectile dysfunction using a combination treatment of low-intensity shock waves (LISW) and platelet rich plasma (PRP) intracavernosal injections. J Sex Med 17(6):S133–S134CrossRef
17.
go back to reference Kitrey ND, Gruenwald I, Appel B et al (2016) Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol 195(5):1550–1555CrossRefPubMed Kitrey ND, Gruenwald I, Appel B et al (2016) Penile low intensity shock wave treatment is able to shift PDE5i nonresponders to responders: a double-blind, sham controlled study. J Urol 195(5):1550–1555CrossRefPubMed
18.
go back to reference Bechara A, Casabé A, De Bonis W et al (2016) Twelve-month efficacy and safety of low-intensity shockwave therapy for erectile dysfunction in patients who do not respond to phosphodiesterase type 5 inhibitors. Sex Med 4(4):e225–e232CrossRefPubMedPubMedCentral Bechara A, Casabé A, De Bonis W et al (2016) Twelve-month efficacy and safety of low-intensity shockwave therapy for erectile dysfunction in patients who do not respond to phosphodiesterase type 5 inhibitors. Sex Med 4(4):e225–e232CrossRefPubMedPubMedCentral
19.
go back to reference Verze P, Capece M, Creta M et al (2020) Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. Asian J Androl 22(4):379CrossRefPubMed Verze P, Capece M, Creta M et al (2020) Efficacy and safety of low-intensity shockwave therapy plus tadalafil 5 mg once daily in men with type 2 diabetes mellitus and erectile dysfunction: a matched-pair comparison study. Asian J Androl 22(4):379CrossRefPubMed
20.
go back to reference Gruenwald I, Appel B, Vardi Y (2012) Low-intensity extracorporeal shock wave therapy—a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med 9(1):259–264CrossRefPubMed Gruenwald I, Appel B, Vardi Y (2012) Low-intensity extracorporeal shock wave therapy—a novel effective treatment for erectile dysfunction in severe ED patients who respond poorly to PDE5 inhibitor therapy. J Sex Med 9(1):259–264CrossRefPubMed
21.
go back to reference Vena W, Vaccalluzzo L, Morenghi E et al (2021) Low-intensity shockwave treatment (liswt) improves penile rigidity in eugonadal subjects with erectile dysfunction: a pilot study. Minerva Endocrinol 48(1):4–11 Vena W, Vaccalluzzo L, Morenghi E et al (2021) Low-intensity shockwave treatment (liswt) improves penile rigidity in eugonadal subjects with erectile dysfunction: a pilot study. Minerva Endocrinol 48(1):4–11
Metadata
Title
Efficacy of low-intensity shockwave therapy with different tadalafil regimens in patients with PDE5 inhibitor-resistant erectile dysfunction: a retrospective cohort study
Authors
Muhammed Arif İbis
Fatih Ozkaya
Zafer Tokatli
Cagri Akpinar
Onder Yaman
Publication date
26-09-2023
Publisher
Springer Netherlands
Published in
International Urology and Nephrology / Issue 2/2024
Print ISSN: 0301-1623
Electronic ISSN: 1573-2584
DOI
https://doi.org/10.1007/s11255-023-03769-w

Other articles of this Issue 2/2024

International Urology and Nephrology 2/2024 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine